Canaccord raised the firm’s price target on Atai Life Sciences (ATAI) to $14 from $11 and keeps a Buy rating on the shares. The firm noted their merger with privatley held Beckley is on track to close in Q4 while recently announcing the FDA granted breakthrough therapy designation (BTD) to Beckley’s BPL-003 (intranasal mebufotenin), which had solid Phase 2 data for treatment-resistant depression.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- ATAI Life Sciences Closes $149.5 Million Public Offering
- 3 Best Stocks to Buy Now, 10/20/2025, According to Top Analysts
- Atai Life Sciences announces FDA breakthrough designation for BPL-003
- Atai Life Sciences price target raised to $10 from $7 at Jefferies
- Atai Life Sciences 23.725M share Spot Secondary priced at $5.48